{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:04:03Z","timestamp":1793963043429,"version":"4.8.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014835","name":"Istituto Nazionale Tumori IRCCS Fondazione Pascale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.eclinm.2023.102113","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:10:51Z","timestamp":1690485051000},"page":"102113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6435-8522","authenticated-orcid":false,"given":"Andrea","family":"D\u2019Arienzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0974-3635","authenticated-orcid":false,"given":"Annarita","family":"Verrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-2577","authenticated-orcid":false,"given":"Martina","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-8952","authenticated-orcid":false,"given":"Fabiana","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Parola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Viggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-5841","authenticated-orcid":false,"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelino","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-2291","authenticated-orcid":false,"given":"Filippo","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102113_bib1","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.3390\/cancers14235936","article-title":"Trop-2 as a therapeutic target in breast cancer","volume":"14","author":"Sakach","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody\u2013drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2023.102113_bib3","article-title":"National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE)","author":"U.S. Department of Health and Human Serivices","year":"2017","journal-title":"V. 5.0"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102113_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.eclinm.2023.102113_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study","volume":"35","author":"Perez","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102113_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102113_bib9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102113_bib10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102113_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.eclinm.2023.102113_bib12","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","article-title":"Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)","volume":"40","author":"Krop","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101463","article-title":"124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive\/HER2-negative (HR+\/HER2-) and triple-negative breast cancer (TNBC): results of part B of SOLTI TOT-HER3 window of opportunity trial","volume":"8","author":"Oliveira","year":"2023","journal-title":"ESMO Open"},{"issue":"4_Supplement","key":"10.1016\/j.eclinm.2023.102113_bib14","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-GS1-05","article-title":"Abstract GS1-05: Datopotamab deruxtecan in advanced\/metastatic HER2- breast cancer: Results\u00a0from the phase 1 TROPION-PanTumor01 study","volume":"82","author":"Krop","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102113_bib15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","article-title":"Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan","volume":"27","author":"Bardia","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.eclinm.2023.102113_bib16","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102113_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib18","first-page":"18","article-title":"Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)","volume":"1","year":"2012","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"25","key":"10.1016\/j.eclinm.2023.102113_bib20","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","article-title":"Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis","volume":"32","author":"Di\u00e9ras","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102113_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100561","article-title":"Final results of the\u00a0global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer","volume":"7","author":"Wuerstlein","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.eclinm.2023.102113_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","author":"Tarantino","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102113_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.eclinm.2023.102113_bib25","first-page":"1","article-title":"Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic","volume":"19","author":"Griffiths","year":"2020","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102113_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"41","key":"10.1016\/j.eclinm.2023.102113_bib27","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102113_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102113_bib29","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"issue":"suppl_5","key":"10.1016\/j.eclinm.2023.102113_bib30","first-page":"S1283","article-title":"LBA15 - Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102113_bib31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.eclinm.2023.102113_bib33","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.annonc.2022.03.185","article-title":"166MO Datopotamab deruxtecan (Dato-DXd)+ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study","volume":"33","author":"Schmid","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib34","series-title":"NCCN guidelines version 1.2023 antiemesis continue","author":"Berger","year":"2023"},{"key":"10.1016\/j.eclinm.2023.102113_bib35","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/j.annonc.2022.03.279","article-title":"LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+\/HER2- breast cancer: final results of the SOLTI TOT-HER3 window of opportunity trial","volume":"33","author":"Prat","year":"2022","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.eclinm.2023.102113_bib36","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib37","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.annonc.2021.03.213","article-title":"LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): preliminary results from an ongoing phase I trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib38","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers14041022","article-title":"Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an Italian expert panel [internet]","volume":"14","author":"Bianchini","year":"2022","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.eclinm.2023.102113_bib39","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.3390\/molecules26237294","article-title":"A\u00a0new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors","volume":"26","author":"Pavone","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102113_bib40","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/00498254.2018.1531158","article-title":"Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys","volume":"49","author":"Nagai","year":"2019","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102113_bib41","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eclinm.2023.102113_bib42","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.638482","article-title":"SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer","volume":"11","author":"Pascual","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib44","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2018.12.022","article-title":"Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1","volume":"109","author":"Montemurro","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102113_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JOP.19.00652","article-title":"Management of cancer therapy-associated oral mucositis","volume":"16","author":"Brown","year":"2020","journal-title":"JCO Oncol Practice"},{"key":"10.1016\/j.eclinm.2023.102113_bib46","series-title":"A\u00a0phase 3, open-label, randomised study of datopotamab deruxtecan (Dato-DXd) versus investigator\u2019 s choice of chemotherapy in patients who are not candidates for PD-1\/PD-L1 inhibitor therapy in first-line locally recurrent inoperable or metastatic","author":"Protocol","year":"2022"},{"issue":"S1","key":"10.1016\/j.eclinm.2023.102113_bib47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2001","article-title":"NCCN task force report: prevention and management of mucositis in cancer care","volume":"6","author":"Bensinger","year":"2008","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.eclinm.2023.102113_bib48","doi-asserted-by":"crossref","first-page":"v139","DOI":"10.1093\/annonc\/mdv202","article-title":"Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"26","author":"Peterson","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102113_bib49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1535-7163.MCT-15-0580","article-title":"Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity","volume":"15","author":"Yan","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102113_bib50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000521933","article-title":"Trastuzumab emtansine-induced nodular regenerative hyperplasia: is dose reduction enough as a preventable measure?","volume":"40","author":"Garrido","year":"2022","journal-title":"Dig Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102113_bib51","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO\u2013EONS\u2013EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102113_bib53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102113_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","article-title":"Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia","volume":"20","author":"Liu","year":"2001","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102113_bib56","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-Positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2023.102113_bib57","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1002\/cncr.27622","article-title":"A\u00a0phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2\u2013positive breast cancer","volume":"118","author":"Beeram","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib58","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","article-title":"Corneal features in trastuzumab emtansine treatment: not a rare occurrence","volume":"175","author":"Deklerck","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"10.1016\/j.eclinm.2023.102113_bib59","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5986-5","article-title":"Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla\u00ae, T-DM1) administration: a case report","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"10371","key":"10.1016\/j.eclinm.2023.102113_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102113_bib62","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1016\/j.annonc.2021.05.524","article-title":"O2-1 datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study\u2217","volume":"32","author":"Shimizu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib63","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","article-title":"Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study","volume":"16","author":"Spira","year":"2021","journal-title":"J\u00a0Thoracic Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib64","doi-asserted-by":"crossref","first-page":"S1386","DOI":"10.1016\/j.annonc.2022.08.012","article-title":"LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HR+\/HER2- metastatic breast cancer (mBC)","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib65","doi-asserted-by":"crossref","first-page":"S590","DOI":"10.1016\/j.annonc.2021.08.1044","article-title":"522P Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials","volume":"32","author":"Chandran","year":"2021","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.eclinm.2023.102113_bib66","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.eclinm.2023.102113_bib67","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.abd.2020.03.005","article-title":"Scalp cooling to prevent chemotherapy-induced alopecia","volume":"95","author":"Silva","year":"2020","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102113_bib69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2023.102113_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102113_bib71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.eclinm.2023.102113_bib72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CMAR.S52256","article-title":"Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel","volume":"5","author":"Bensadoun","year":"2013","journal-title":"Cancer Manag Res"},{"issue":"9815","key":"10.1016\/j.eclinm.2023.102113_bib73","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(11)61092-1","article-title":"Breast cancer in pregnancy","volume":"379","author":"Amant","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1078\/0344-0338-00347","article-title":"Case control study of novel prognostic markers and disease outcome in pregnancy\/lactation-associated breast carcinoma","volume":"199","author":"Aziz","year":"2003","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.eclinm.2023.102113_bib75","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/eci.10.77","article-title":"Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge","volume":"6","author":"Azim","year":"2010","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.eclinm.2023.102113_bib76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ctrv.2015.03.001","article-title":"Targeted agents for cancer treatment during pregnancy","volume":"41","author":"Lambertini","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102113_bib77","doi-asserted-by":"crossref","first-page":"967","DOI":"10.7150\/ijms.32752","article-title":"Management of chronic respiratory failure in interstitial lung diseases: overview and clinical insights","volume":"16","author":"Faverio","year":"2019","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.eclinm.2023.102113_bib78","series-title":"StatPearls [internet]","article-title":"Interstitial lung disease","author":"Antoine","year":"2021"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102113_bib79","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a\u00a0position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102113_bib80","first-page":"356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102113_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"key":"10.1016\/j.eclinm.2023.102113_bib82","series-title":"San Antonio breast cancer Symposium","first-page":"8","article-title":"Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer","author":"Modi","year":"2020"},{"key":"10.1016\/j.eclinm.2023.102113_bib83","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.annonc.2021.08.562","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01)","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102113_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102113_bib85","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19","volume":"5","author":"Struyf","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eclinm.2023.102113_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eclinm.2023.102113_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.enz.2017.08.001","article-title":"Circulating peptidome and tumor-resident proteolysis","volume":"42","author":"Fan","year":"2017","journal-title":"Enzymes"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102113_bib88","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.analchem.6b00976","article-title":"Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma","volume":"88","author":"Wei","year":"2016","journal-title":"Anal Chem"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023002900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:19:45Z","timestamp":1762899585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023002900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":87,"alternative-id":["S2589537023002900"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102113","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102113"}}